Personalized ctDNA monitoring in metastatic HR+/HER2− breast cancer patients during endocrine and CDK4/6 inhibitor therapy by Jesús Fuentes-Antrás, Mitchell J. Elliott, Sasha C. Main, Philippe Echelard, Aaron Dou, Philippe L. Bedard, Eitan Amir, Michelle B. Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Emily Van de Laar, Celeste Yu, Yangqing Deng, Lisa Gates, Clodagh Murray, Christopher G. Smith, Amber Chevalier, Scott V. Bratman, Lillian L. Siu, Hal K. Berman, David W. Cescon

Get full text